ARISING HEALTHALIVE. AWAKE. AWARE.Read the magazines →

← All editions

THE ARISING · EDITED READER EDITION

The Arising · November 16 Edited Reader Edition

This edited reader edition includes 21 reviewed articles from November 16, 2026. It is not the complete original issue. It includes 21 of the original 36 stories; 15 are not included here.

Listen to The Arising Signal →

Longevity & Healthspan

What Britain’s sugar rationing can tell us about biological age

An early-life policy change left a small signal in adult blood measures. It did not show that anyone aged more slowly.

In September 1953, Britain ended postwar sugar rationing. Two people born only months apart could therefore have spent very different amounts of early life under the policy. Researchers used that timing to ask whether early nutritional conditions might leave a trace decades later.

The study analyzed 54,201 UK Biobank participants. Birth dates estimated how much of the first 1,000 days, from conception through about age two, overlapped rationing. The researchers could compare policy exposure; they could not reconstruct what an individual family actually ate. For some participants the estimated exposure was limited to pregnancy. For others it extended into childhood.

A small difference in a one-time measurement

The researchers calculated PhenoAge from chronological age and nine blood markers, including glucose and creatinine. In adjusted comparisons, people estimated to have experienced rationing scored about three-tenths of a year lower relative to their chronological age. The difference approached half a year in the longest-exposure group.

That phrasing can sound like extra time gained. It isn’t. These measurements were taken in adulthood, not repeated over decades to measure a person's rate of aging. The result does not establish that participants lived longer or that the difference can guide care for an individual.

What the history adds

The abrupt policy change is a useful alternative to asking people to recall their infant diets decades later. It still cannot isolate sugar itself from other changes around that time. There can be differences across birth cohorts, and the study only included people who survived and were able to take part in the Biobank.

The useful question is not whether a commercial age test can tell you how much time you have left. It is whether conditions we barely remember from our earliest years can leave signals researchers can measure much later. This study makes that question more concrete, without settling it.

Sources and further reading

Primary research in Nature Communications · The Arising: biological clocks

Open this article on its own →

Longevity & Healthspan

Shingles Vaccination and Dementia: An Encouraging Link, Not Proven Prevention

Shingles vaccination has an established purpose: preventing shingles and its complications. A separate question has emerged from studies of older adults: could vaccination also reduce the chance of a later dementia diagnosis?

A new systematic review in Vaccines examined 36 reports, 25 of them primary investigations. Across several kinds of studies, the results generally pointed toward fewer dementia diagnoses among people who received a shingles vaccine. But the reviewers graded the certainty for every dementia outcome very low. They concluded that the evidence does not support a dementia-prevention indication.

One of the most informative comparisons comes from Wales. When it introduced an older, live shingles vaccine, eligibility depended on a strict date-of-birth cutoff. A study in Nature compared people born just before and just after that cutoff. Rather than comparing people who freely chose whether to get vaccinated, the researchers used the change in eligibility to estimate the effect of receiving the vaccine.

The estimate was 3.5 percentage points fewer new dementia diagnoses over seven years, with a 95% confidence interval of 0.6 to 7.1 points fewer. That is an absolute difference. The relative difference was estimated at about 20%. Both figures describe the same comparison, and neither is an expected effect for everyone who gets vaccinated today.

The design is stronger than simply comparing volunteers with non-volunteers, but it still depends on assumptions about how similar the groups were around the cutoff. It used a different vaccine from the one the CDC currently recommends in the United States. It also counted diagnoses; that does not establish whether the onset of disease changed, rather than when it was detected.

People can ask about shingles vaccination for its established purpose without waiting for the dementia question to be settled. That question deserves its own trials and its own evidence.

Sources

Open this article on its own →

Women’s Midlife

Menopause is not one story

A UK study found different patterns of sleep, mood and concentration symptoms across stages of menopause and among people whose menopause began naturally or after surgery.

When someone says, “I haven’t felt like myself lately,” the next question doesn’t have to be, “Are you sure it’s menopause?” It might be, “What changed first?”

That question sits underneath a new study of menopause experiences across the UK. The researchers asked people about anxiety, mood, sleep, pain and quality of life. They wanted to see whether the answers differed depending on where people were in the transition and how menopause began.

What the researchers heard

The study included 845 people at the first survey and 538 at follow-up. The median age was 52. The researchers used symptom questionnaires at two points and conducted interviews with a subset of participants.

The people in perimenopause reported more severe anxiety than those in postmenopause at both survey points. Difficulty concentrating and forgetfulness were also most pronounced in the perimenopause group. Participants who had experienced surgical menopause reported more depressive symptoms and insomnia than those who had reached menopause naturally. The researchers also reported differences in hot flashes or night sweats, back pain and quality of life.

Those patterns are a reason to ask questions, not a symptom list everyone in a group should expect to match. A higher score on a depression questionnaire is not a diagnosis. And without seeing the full group estimates, we can’t tell from the abstract how large these differences would feel in daily life.

Why the timeline matters

The researchers did not assign people to surgery or natural menopause. The groups may have differed in what brought someone to surgery, the symptoms they had before it, and what care they received afterward. Not everyone answered the follow-up survey, either. The study can identify experiences that traveled together; it cannot tell us whether surgery itself caused those differences or whether a particular treatment would help.

Still, it’s useful to tell the story in order. If sleep changed after a procedure, say so. If the worry or low mood was there before the sleep changed, say that too. A short note with three things can make an appointment more concrete: when the symptom started, how often it happens, and what it stops you from doing. The point is not to decide the cause yourself. It’s to give you and your clinician a more specific place to start.

Source: Delanerolle et al., MARIE UK-WP2a prospective mixed-methods study, Menopause, November 10, 2026. This article is based on the published study abstract. General education, not individual medical advice.

Open this article on its own →

Sleep & Circadian Health

Food and Housing Security Were Linked to More Regular Sleep

Most sleep advice starts at bedtime. A study in JAMA Network Open started with a different question: are the circumstances in which people live reflected in how long and how consistently they sleep?

Researchers analyzed records from 12,403 adults in the National Institutes of Health’s All of Us Research Program who had at least 180 days of Fitbit sleep data. The median observation period was 982 days. The researchers compared wearable estimates of sleep with survey answers about social connections, economic stability, neighborhood conditions and access to health care.

After adjustment for several differences between participants, people in the top third of the combined social conditions score slept an estimated 5.8 minutes longer per night than people in the bottom third. The 95% confidence interval ran from 3.8 to 7.8 minutes longer. The statistical measure of night-to-night variation in sleep length was about 4.8 minutes lower in the more advantaged group.

Economic stability, as defined in the survey, showed the strongest association among the domains examined. People reporting food security and no housing problems averaged 10.7 minutes more sleep than people reporting both food insecurity and housing problems, with a confidence interval of 5.3 to 16.1 minutes.

These are group averages from observational data. The study did not assign housing or financial assistance, and it did not show that changing either would add a specific number of minutes to someone’s sleep. The wearable estimates are not a clinical sleep test, and the clinical significance of these modest differences is uncertain. Participants were disproportionately White and college educated; the pattern may not apply equally to other groups.

The findings are a reason to ask what gets in the way of sleep before assuming bedside habits are the entire problem. They are not a reason to chase a few minutes on a device. A better next study would ask whether changes in living conditions are followed by changes in sleep, and whether those differences matter to people during the day.

Sources

Open this article on its own → Sleep and circadian rhythms →

Nutrition

High-Protein Diets and Kidney Health: What Shorter Trials Leave Unanswered

A high-protein diet is often discussed as if it were a single decision with a single answer. A new review in Nutrition shows why the kidney question is more specific: how much protein, for how long, and in people with what starting kidney function?

The authors examined past research rather than conducting a new experiment. Their narrative review found that randomized trials generally had not shown clinically significant deterioration in kidney function over short- to medium-term follow-up. Some observational studies linked higher intake to a faster decline in estimated kidney filtration, particularly among people with chronic kidney disease or cardiometabolic risk factors.

The two types of evidence have different strengths. Random assignment helps separate diet from other differences between people, but a short trial can miss effects that take years to appear. Longer observational studies can see those later events, but people who eat different amounts of protein may differ in ways that the studies cannot fully account for. Taken together, the findings do not establish long-term safety or a single protein target for everyone.

Chronic kidney disease is a separate clinical context, not a footnote to studies of healthy people. KDIGO's 2024 guideline suggests about 0.8 grams of protein per kilogram of body weight per day for adults in stages G3 through G5, and advises adults with chronic kidney disease at risk of progression to avoid intakes above 1.3 grams per kilogram per day. These are guidance for specified patient groups, not personal targets. Nutritional status, risk of undernutrition and other medical circumstances matter.

The practical question isn't whether protein is good or bad. It's what intake fits your kidney health and nutritional needs. For people with kidney disease, that is a conversation with their clinician or a renal dietitian, not a number to borrow from a fitness plan.

Sources

Open this article on its own → Nutrition →

Nutrition

What happened when older adults ate walnuts for two years?

A randomized trial did not detect a clear difference in weight or total body fat. That’s different from proving that what you add to a diet never matters.

A food can be high in calories and still fit into an ordinary diet. But if researchers ask people to eat it regularly, what happens to their weight over time? The Barcelona arm of the Walnuts and Healthy Aging trial offers a longer look than most feeding studies.

The researchers assigned 352 older adults either to include walnuts in their usual diets or to avoid them. Of those enrolled, 326 finished the two-year study. Participants assigned to walnuts ate a median of 43 grams a day, about an ounce and a half. The team assessed weight and also used scans to compare body composition.

What the measurements showed

The analysis did not detect a clear difference between groups in body weight or in total body fat. Some body-composition measures shifted over time within both groups. One secondary measure of fat distribution differed modestly among women, but it did not indicate that the walnuts group had less total body fat.

That is a useful distinction. A trial that does not detect a difference cannot show that the diets are equivalent under every condition. It does not tell us what happens with larger portions, different eating patterns, or in people outside the older group studied. The analysis also focused on people who finished the study. The California Walnut Commission supported the work, and the paper discloses author ties to it.

The practical question

The study adds a useful piece of evidence about adding one specific food in one real-world setting. It is not a test of unlimited portions or a rule that applies to everyone. If you want to understand what a food is doing in your own diet, a good first question is what it replaces, if anything. A second is which outcome you actually care about, rather than treating a number on the scale as the whole answer.

Sources and further reading

Ros and colleagues, randomized WAHA trial analysis in Nutrients · The Arising: nutrition

Open this article on its own →

Women’s Midlife

Can a short questionnaire help put perimenopause symptoms into words?

A new 16-item scale performed consistently in a U.S. validation study. It is not a diagnosis, and the study did not test whether the scale improves care.

“I haven’t felt like myself” can be an honest place to start a visit. The next useful detail is often what changed, when it happens, and what it gets in the way of. A new questionnaire tries to give women and researchers a more consistent way to put those details into words.

The researchers recruited 1,255 U.S. women ages 35 to 59 through an online panel. Of those, 633 identified themselves as perimenopausal. The questionnaire asks about symptoms over the past month in several areas, including hot flashes and night sweats, mood, physical concerns, and sexual symptoms.

How researchers checked it

When participants completed the questionnaire again a week or two later, scores were reasonably consistent. The study reported a test-retest reliability measure of 0.82. The scores also tracked closely with those on a commonly used menopause rating scale, with a correlation of 0.88. That supports the questionnaire as a way to describe symptoms consistently. It does not tell us whether a particular symptom was caused by perimenopause.

The study relied on self-reported reproductive stages rather than confirming each participant’s stage clinically. The questionnaire does not score changes in bleeding patterns, and neither diagnosis nor the benefit of any treatment was tested. The team included researchers affiliated with Flo Health and Mayo Clinic. A separate question is whether using the scale in routine care helps patients get better answers or support.

What to take into a visit

A short list can be useful with or without this particular scale. Which symptoms wake you, interrupt work, or make you change your plans? How often does that happen? How long has it been going on? A questionnaire can help organize that account, but it cannot replace the context you bring or the clinician’s assessment.

Sources and further reading

Primary validation study in Menopause, indexed by PubMed · The Arising: women’s midlife

Open this article on its own →

Clinical Research

A weekly HIV pill passed an important test. Who took it matters.

A phase 3 trial found that, for adults already doing well on a specific daily HIV regimen, switching to once-weekly treatment met the trial’s standard for maintaining viral suppression at 48 weeks.

A treatment schedule shapes a life. Taking a pill every week instead of every day would be a change that some people might welcome. But the first question about a new schedule isn’t whether it sounds easier. It’s what happened when people tried it, and who got the chance to try.

ISLEND-1 enrolled 607 adults across 12 countries. All had HIV-1 that was already suppressed for at least six months while taking the same daily combination of bictegravir, emtricitabine and tenofovir alafenamide. The researchers randomly assigned some of them to switch to weekly islatravir and lenacapavir, while the others continued their daily regimen. Participants and researchers were blinded to who received which active treatment, and participants took matched placebos on the other schedule. So the trial compared the medications under controlled conditions, not what it feels like to take only one pill a week in everyday life.

Why “zero versus one” isn’t the whole result

At week 48, under the study’s rules, none of the 304 participants assigned to weekly treatment and one of the 303 assigned to daily treatment had an HIV RNA level of 50 copies per milliliter or higher. The estimated difference was 0.3 percentage points in favor of the weekly group, with an uncertainty interval that also allowed for a small difference in the other direction. The result met the trial’s prespecified noninferiority standard: the upper end of that interval was below the four-percentage-point margin the study set in advance.

That zero is easy to remember. It is not the same as saying everyone who switched had documented suppression. A result below 50 was documented for 93.4% of the weekly group and 92.4% of the daily group under the trial’s analysis. Serious adverse events occurred in both groups, in 5.3% and 4.6% of participants, respectively. Those counts alone do not tell us that either regimen is safer.

This was a switch study, not a study of starting treatment

ISLEND-1 tested a specific switch in people whose existing medication was already keeping their virus suppressed. It did not test starting treatment in someone with an unsuppressed viral load, or show that a weekly schedule improves adherence in people who have trouble taking a daily pill. It also did not prove the regimens are interchangeable.

What the trial added is narrower and useful: a weekly regimen cleared a prespecified 48-week test in the people studied. If the appeal of a different schedule is that it might fit your life better, that is a good subject to bring to your HIV care team. Don’t change your regimen based on this study.

Source: Rockstroh et al., ISLEND-1 phase 3 randomized trial, The New England Journal of Medicine, October 1, 2026 issue. The study was funded by Gilead Sciences and Merck Sharp & Dohme. This article is based on the published study abstract. General education, not individual medical advice.

Open this article on its own →

Longevity & Healthspan

Starting Regular Activity After 60 Was Linked to Better Physical Function

What happens after someone who has not been regularly active starts moving more in later life? In a U.S. observational study, older adults who reported starting moderate or vigorous activity had fewer physical limitations later than those who remained below that activity threshold.

The researchers used the U.S. Health and Retirement Study, drawing on records from 7,463 adults aged 60 and older between 2004 and 2018. They arranged the survey data to resemble four successive trials. That approach, called target trial emulation, makes the comparison more systematic but does not randomly assign people to exercise. Participants who had been below the activity threshold at the previous survey and then reported moderate or vigorous activity at least weekly were counted as starters.

Over two, four and six years, people who reported starting had lower physical limitation scores among those still alive. On a separate combined outcome, they were less likely to report a new difficulty with basic daily activities or to die. At two years, the estimated risk ratio for that combined outcome was 0.84 (95% confidence interval, 0.78 to 0.92). At six years it was 0.91 (0.85 to 0.97). These are relative estimates for the combined outcome, not individual estimates of either death or loss of independence.

The survey measured how often people were active, not the length of each session or weekly minutes. The study cannot show that one session a week is enough for any particular benefit. It also cannot fully rule out differences in health that made some people more able to begin exercising, or bias from comparing functional scores only among survivors.

The lesson is not to wait until a perfect weekly target feels possible. This study followed a practical transition, from below a threshold to reporting regular activity. Determining what amount and kind of movement helps preserve independence will need studies that measure those details directly.

Sources

Open this article on its own →

Environment & Health

A Green-Space Study Found Diminishing Returns, Not a Prescription for Time Outdoors

How much time in green space is enough to make a difference? Researchers found a pattern in earlier studies, but it is not a timetable for treating anxiety or depression.

The analysis in the Journal of Environmental Psychology modeled how visits to green space related to several mental health outcomes. The researchers looked at two questions separately: how often people visited, and how much total time they spent in green space each week. The curves rose most at lower exposure levels, then began to flatten.

On the duration curve, about one hour per week corresponded to half of the largest response estimated by the model, and about four hours corresponded to roughly 90% of that modeled response. Those percentages are not declines in symptoms. They describe positions on a statistical curve, not what any individual can expect from a given amount of time outdoors. A separate model for visit frequency is not an instruction for how to divide up those hours.

The findings draw on observational evidence. The people who spend more time in a park may differ from people who cannot get there, and mood or health can affect who goes out in the first place. The analysis does not establish that an extra hour outdoors will cause a specific improvement, or that nature can replace mental health care.

The results raise a practical question for communities: who has green space that is easy and comfortable to reach? A park drawn on a map is not necessarily a park anyone can use. The next useful studies would measure access, what people do once they get there, and whether changes in those conditions change outcomes.

Sources

Open this article on its own →

Metabolic Health

When blood sugar improves, do blood vessels recover?

A new review asks why some measures of blood vessel function improve after blood sugar falls while others do not.

A blood sugar result can tell you that glucose control has improved. It does not also tell you how an artery responds to increased blood flow. In a review of laboratory experiments and human studies, Yuanye Gu and colleagues looked at what happens when researchers treat those as two separate outcomes.

They focused on the endothelium, the thin layer of cells that lines blood vessels and helps regulate how they behave. The authors found reports in which some measures of endothelial function stayed abnormal after blood sugar improved. In some human studies, selected vessel responses in the forearm or skin improved. Others found no detectable change in how well an artery widened in response to increased blood flow. These tests measure different things, so an improvement in one does not settle what happened in the others.

When did the intervention start?

In some experimental models, interventions started during glucose lowering helped arteries relax or reduced leakage from very small blood vessels. But that does not answer what happens when an intervention begins only after a vessel problem has been shown to persist despite stable glucose improvement. The authors found limited evidence for lasting reversal in that second situation.

The distinction also applies to proposed mechanisms. Better readings from mitochondria, the structures cells use to produce much of their energy, do not on their own show that a vessel works better. And an improvement in vessel function is not the same as evidence that fewer people will have heart attacks or strokes. Those outcomes need to be measured separately.

This is a targeted narrative review, not a new trial or a pooled estimate. It does not show that glucose control lacks benefit or that damage cannot be repaired. It points to the study that would help answer the question: document the deficit after glucose levels have stabilized, then test whether an intervention improves vessel function and whether that improvement lasts.

Source: Gu et al., Persistent Endothelial Dysfunction after Glycaemic Improvement, Frontiers in Endocrinology. Accepted November 2, 2026. Review scope: the publisher’s accepted abstract; the formatted article was not available at review.

Open this article on its own →

Brain Health

Training the Body and Mind Together Improved Some Cognitive Test Scores in Older Adults

Daily life often asks people to think and move at the same time. Trials have put that idea into exercise programs, combining movement with a mental challenge. A new review found better performance on some cognitive tests in older adults who took part in such programs. It is less clear which program to choose or what changes in daily life.

The review in BMC Geriatrics included 20 randomized trials with 1,402 older adults. The analysis combined 93 estimates from those trials and accounted for the fact that several estimates came from the same participants. The tested programs paired physical activity with a cognitive task, either at the same time or as part of the movement itself. The comparison conditions varied.

The combined result favored dual-task training: the standardized difference, called Hedges’ g, was 0.55 (95% confidence interval, 0.24 to 0.85). That is a way of putting different tests on one scale. It is not a 55% improvement. Results varied substantially across trials.

The clearest pooled results were for overall cognitive performance, planning and other executive skills, memory, and processing speed. Evidence was uncertain for attention and working memory. The analysis did not find one clearly superior format, program length or participant subgroup. That is not evidence that all versions work equally well.

Better test performance does not establish that a program prevents dementia or helps someone remain independent. It also does not mean that adding distractions to an ordinary walk is wise, particularly for someone already concerned about balance or falls. The result is a reason to study well-designed, appropriately supported programs, with cognitive tests and everyday outcomes measured side by side.

Sources

Open this article on its own →

Movement

Tai Chi Showed a Mobility Signal in a Review of Four Movement Practices

How quickly can someone rise from a chair, walk a short distance, turn and sit down again? In a review of four traditional Chinese movement practices for older adults, Tai Chi showed an improvement on that specific test. The results did not establish that Tai Chi is the only useful practice, or that every older adult should start with it.

The review in Frontiers in Public Health compared Tai Chi, Baduanjin, Yijinjing and Wuqinxi across 20 randomized trials involving 1,746 adults aged 60 and older. Many trials did not compare the practices directly. The researchers also used indirect comparisons through shared controls, such as usual activities, health education or other interventions.

For the Timed Up and Go test, Tai Chi performed better than the conventional control conditions. The standardized difference was −0.55 (95% confidence interval, −1.01 to −0.08), where a negative value indicates a faster performance. This is a standardized estimate, not 0.55 seconds. The other practices did not show clear differences from control on that outcome. Fewer studies tested those practices, and an uncertain estimate is not evidence of no benefit.

The review did not establish clear benefits over controls on handgrip strength or the balance outcome it examined. Evidence there was low to very low certainty. Nor did this analysis establish a reduction in falls or identify a weekly schedule that works for everyone.

A mobility test can tell us something concrete without telling us everything. For readers interested in Tai Chi, this study offers a reason to ask about a class with support appropriate to their ability. It does not establish that a particular class is suitable after a recent injury or for someone at high risk of falling. Larger direct comparisons would help explain which practices work best for which goals.

Sources

Open this article on its own →

Brain Health

Creatine and cognition: a signal in a small trial

A four-week study in physically active women found differences on several cognitive tests. It did not show that creatine protects against cognitive decline.

A faster response in a lab test and a sharper memory years from now are two different outcomes. A small creatine trial offers some evidence about the first. It leaves the second open.

Researchers enrolled 48 physically active women, 26 younger and 22 older. They randomly assigned participants to take either creatine monohydrate or a placebo for 28 days. The creatine group took three grams daily as part of the study protocol. Before and after the trial, participants took a series of tests that measured different thinking skills.

Compared with placebo, the clearest signals appeared on tests of how quickly participants responded to sights and sounds, how well they held back an automatic response, and how well they kept information in mind long enough to use it. The authors reported improvements in both age groups. Some results looked stronger in older participants. The groups also differed in how much creatine the researchers estimated they were getting from food at the start, and the authors accounted for that in their analysis.

What counts as a meaningful change?

The trial was small; the older group had only 22 participants before it was split between creatine and placebo. The researchers also looked at many outcomes in an exploratory analysis. A stronger signal in one age group is a lead to test, not proof that age determines who benefits. The study abstract does not give enough detail to judge how large these changes might feel outside a testing room.

Four weeks of reaction-time and memory scores do not tell us whether someone will remember appointments more easily, stay independent longer, or be less likely to develop dementia. A larger study with a main outcome chosen in advance and follow-up beyond a month would help show whether the result is reproducible and whether it matters in daily life.

Source: Oliveira et al., Creatine Supplementation on Cognition in Young and Old Active Females, Biological Research for Nursing, November 2, 2026. Review scope: published study abstract.

Open this article on its own →

Longevity & Healthspan

Eating less can change health markers. Does it add years?

Calorie restriction improved several measurements in a two-year human trial. Animal studies help explain why that still doesn’t tell us what would happen to a person’s lifespan.

If a study reports lower blood pressure, we can say it measured lower blood pressure. We can’t turn the result into years of life unless researchers measure that outcome too. Calorie-restriction research makes it tempting to skip that step because the studies in people and animals seem to tell one story. Look at what each study actually counted and the story becomes more interesting.

The comparison changes the answer

In 2010, Bronwen Martin and colleagues raised a problem with a common control group in rodent research: many animals kept under standard laboratory conditions eat freely and move little, and can develop metabolic problems. If the comparison starts with an unhealthy control group, the size of a benefit may tell us something about the conditions the control animals lived in. That argument doesn’t show that the entire effect of calorie restriction goes away in healthy animals. It shows why the starting point matters.

Another 2010 study made the point in a different way. Chen-Yu Liao and colleagues tested a 40% reduction in food intake across 41 strains of inbred mice. At that level, restriction shortened lifespan in more strains than it lengthened it. A 2024 Nature study of 960 genetically diverse female mice found that greater restriction extended lifespan on average in its population, but genetics had more influence on lifespan than diet assignment. The most restrictive diet also reduced lean mass. Lower fasting glucose and reduced body fat did not track with longer life in that study.

The studies did not test the same populations under the same conditions. Taken together, they show why neither “it works in mice” nor “it doesn’t work in mice” is much of an answer. The animals, the amount of restriction and the outcome all matter.

What the human trial measured

In CALERIE, researchers compared a two-year calorie-restriction program with a control group among healthy young and middle-aged adults without obesity. The main report included 218 participants. The intervention group averaged about a 12% reduction in calories, rather than the 25% the program aimed for. An exploratory analysis of the trial found lower LDL cholesterol and blood pressure, along with improvements in insulin sensitivity and some other measures. These are changes in risk factors, not a count of heart attacks prevented or years gained.

A later analysis of blood samples added a different kind of result. One DNA-based measure, DunedinPACE, shifted modestly in the direction of slower aging. Two other measures, PhenoAge and GrimAge, did not show significant changes. These tools use different patterns of chemical marks on DNA. A change in one is worth investigating. It is not a substitute for observing whether people lived longer or stayed healthy longer.

The trial tells us that a supervised change in food intake can move several measurements over two years in a selected group. It doesn’t tell us how much longer a healthy person would live, or whether continuing the intervention for decades would yield a net benefit. Those are questions about actual lives, and they need studies that follow actual lives for longer.

Sources: Martin et al., rodent control conditions, PNAS, 2010; Liao et al., inbred mouse strains, Aging Cell, 2010; Di Francesco et al., genetically diverse mice, Nature, 2024; Ravussin et al., CALERIE main two-year report, Journals of Gerontology: Series A, 2015; Kraus et al., CALERIE cardiometabolic outcomes, The Lancet Diabetes & Endocrinology, 2019; Waziry et al., CALERIE DNA-methylation analysis, Nature Aging, 2023.

Open this article on its own →

Science & Discovery

An ancient Mars rock, sampled on the second try

Perseverance couldn't core Badger Peak. A nearby rock gave the rover its first new sample in more than a year.

When NASA’s Perseverance rover ground a patch into a pale boulder west of Jezero crater, it exposed a striking pattern of light and dark minerals. But making a window into the rock and taking a piece of it were two different jobs. Badger Peak, as the team called the spot, proved too hard to core.

The setback came as Perseverance explored Lac de Charmes, a landscape of valleys and ridges outside the crater’s western rim. In its September update, the mission team described the rocks there as among the oldest the rover had encountered. They precede Jezero’s river and lake sediments. That comparison doesn’t give them an exact age, and it doesn’t make them older than every crater on Mars.

By that update the rover had made 13 abrasion patches during its survey. The patches let its instruments look beneath weathered surfaces without having to take the rock away. Some of the rocks looked as though they formed from cooling molten material; others showed evidence of impact. Some bore traces of both.

The second attempt

Rather than give up on that kind of rock, the team moved about 100 meters to another patch of pale boulders. Images and chemical measurements suggested a composition similar to Badger Peak's. This time the team chose a flatter surface and used a less-worn bit. On October 24, the drill made it about 3.1 centimeters into the rock. The resulting sample, Singita, was Perseverance’s first in more than a year.

Singita may be among the oldest rocks in the rover’s collection, according to the mission team. Its texture suggests that it likely formed deep in the Martian crust and was later altered and brought toward the surface by one or more impacts. Those are interpretations of the rock, not an exact age or a confirmed sequence of events.

The sample is on Mars. Taking it is a result; getting it into an Earth laboratory would be a separate achievement. The rover’s own observations already offer something worth following: a record of how the team recognized a rock it wanted, failed to core it, and found another way to ask the same question.

Sources: NASA Science, Mars Has Its Charmes (September 28, 2026 page; field note dated September 21) and Newest Sample, Oldest Rock? (November 9, 2026 page; field note dated November 1).

Open this article on its own →

Longevity & Healthspan

In Mice, Recipient Age Mattered More Than T-Cell Age for Artery Stiffness

What makes an artery stiffen with age? A mouse experiment tested one specific possibility: whether the age of a type of immune cell changes how stiff an older animal’s arteries become.

Researchers transferred T cells from young or old mice into young or old recipient mice that lacked their own mature T and B cells. Five weeks later, they measured how quickly the pressure wave from a heartbeat traveled along the arteries. This measure, called pulse wave velocity, generally increases as arteries get stiffer.

The older recipients had higher pulse wave velocity regardless of whether their donor T cells were young or old. Donor age did affect the mix of T-cell states the team observed, but those differences did not translate into a clear difference in arterial stiffness in this experiment.

That is narrower than saying immune cells do not matter to vascular aging. The experiment varied the age of one type of immune cell in a particular mouse model. An older recipient differs from a younger one in many ways, so the result does not isolate the artery wall from everything else in the animal’s environment. It also does not establish a treatment strategy in people.

The result gives researchers a useful next question: which changes in older recipients make their arteries stiffer, and would changing any of those features make a difference?

Sources

Open this article on its own →

Longevity & Healthspan

NIH Asks What Menopause Studies Should Measure in Common

When two studies ask about menopause using different definitions and different questionnaires, their answers can be hard to compare. The National Institutes of Health is asking what information researchers could collect more consistently.

The November 9 request for information is about common data elements: agreed definitions for the questions researchers ask and the answers they record. The notice seeks input from researchers, clinicians, patient advocates, data standards experts and the public. The published deadline is December 18, 2026.

The request covers more than hot flashes. NIH asks for feedback on reproductive history, menopause timing and type, symptoms, and how these experiences can be measured in research and care settings. The notice recognizes that validated tools already exist. The problem is that studies and clinics do not consistently use the same ones, making it harder to combine or compare their findings.

A common definition also has limits. For example, questions about when symptoms began and when menstrual cycles changed answer different things. Surgical or medically induced menopause can raise questions that a questionnaire designed around a natural transition will not fully capture. Useful standards will need to make those distinctions visible.

This is a request for input, not a new clinical requirement or a finalized set of measures. Its immediate value is the opportunity to point out where existing questions fail to capture what patients experience and where a shared definition would make evidence easier to interpret.

Sources

Open this article on its own →

Longevity & Healthspan · Long Reads

A Study of Cellular Recycling Found a Control Point, Not a Treatment

Cells have a system for collecting and recycling some of their contents. Researchers studying that system have identified a way a protein changes shape and takes on a different job. It is a result about how a cell works, not about a treatment people can use.

The study, published in Nature Communications, focused on a protein called LC3. When attached to the membrane of an autophagosome, a compartment that gathers material for recycling, LC3 helps bring in proteins that connect it to its cargo. The research team found that contact with the membrane changes LC3’s shape and exposes binding sites that are less accessible when the protein is free inside the cell.

To check the mechanism, the team compared two engineered forms of LC3. One favored the active shape and helped recruit receptors and capture cargo in the experiments. The other remained functionally inactive even when it was on the membrane. The researchers tested these differences with structural measurements and microscopy, among other methods.

The word “switch” can make this sound like a drug or outside signal that turned recycling up or down. That is not what the study showed. The researchers compared altered forms of the protein in laboratory experiments. They did not test a supplement, fasting routine, or treatment in people. And capturing more cargo is not, on its own, evidence of better health.

What the work adds is a clearer view of one step in a complicated process. With that step better understood, researchers can ask when changes in cargo capture matter and when the rest of the system is the limiting factor.

Sources

Open this article on its own →

Markets & Strategy · Long Reads

The Google Power Deal Shows Why New Capacity and Power Contracts Are Different

A power deal can support existing generation or help add new generation. Those are both useful to a buyer planning for years of demand, but they are not the same thing. An October agreement between Google and Constellation makes the distinction unusually visible.

The companies announced a 20-year power purchase agreement to support roughly 890 megawatts of additional generating capacity across 11 existing nuclear units in Illinois, Pennsylvania and New Jersey. This is an expansion of output at existing units, known as an uprate, rather than construction of 11 new reactors. Constellation expects the first uprate to deliver power in 2028 and says the work will support more than $4.3 billion in investment. Those are company plans, not megawatts already in service.

The companies separately announced a 15-year energy supply agreement for another 2,700 megawatts from the PJM fleet. Adding the two figures gets to roughly 3.6 gigawatts of arrangements. It does not mean the agreement is building 3.6 gigawatts of new generating capacity.

That distinction matters when a community asks what infrastructure a major customer will bring. A contract for existing supply tells you something about how that customer expects to buy power. A project to raise generating capacity tells you something about potential future output. Neither number by itself tells you when a particular data center will connect, what local equipment it will need, or who will pay for those local changes.

The questions worth tracking are plain ones: how much output is new, when is it expected, and what still has to happen before it is available? Those questions make an announcement more useful than its largest headline number.

Sources

Open this article on its own →

Science & Frontiers

Singapore Is Building a Place in Fusion’s Supply Chain

Fusion companies need parts, diagnostic instruments and engineering teams long before they can sell power from a commercial plant. Singapore’s early move is to build a role supplying some of that work.

At FusionX:APAC on October 1, Singapore’s energy and industry minister, Tan See Leng, pointed to precision engineering, advanced manufacturing and plasma diagnostics as areas where Singapore can contribute. His remarks described existing collaborations. They did not announce that Singapore would build a commercial fusion plant.

One collaboration is with Commonwealth Fusion Systems. Singapore’s Agency for Science, Technology and Research, known as ASTAR, says it and ST Engineering helped make components for SPARC, the company’s demonstration machine. In May 2026, ASTAR announced a separate five-year research agreement with the company to work on technologies for future power plants, including the proposed ARC design.

A demonstration machine and a commercial power plant answer different questions. Supplying components for a demonstration is evidence of engineering work underway. It does not show that a utility can sell fusion electricity at a particular price, or that the commercial plant will arrive on a particular schedule.

For places that already have skilled manufacturers, that split is worth noticing. There may be work to do on demanding components and measurements without staking the entire strategy on a finished power plant. The next evidence to watch is what these collaborations deliver, who buys it, and whether the skills prove useful across more than one project.

Sources

Open this article on its own →

THE ARISING NEWSLETTER

Science moves forward.
Come with it.

Research, clear explanations, and a little room for wonder.
Read and follow The Arising on Substack.

Find The Arising on Substack ↗